^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AGR2 elevation

    i
    Other names: AGR2, Anterior gradient 2, Protein Disulfide Isomerase Family A, Member 17, Secreted Cement Gland Protein XAG-2 Homolog, Anterior Gradient Protein 2 Homolog, HAG-2, HPC8, AG2, Anterior Gradient 2 Homolog, Epididymis Secretory Protein Li 116, Secreted Cement Gland Homolog, Anterior Gradient Homolog 2, HEL-S-116, PDIA17, GOB-4, XAG-2
    Entrez ID:
    10551
    Related biomarkers:
    Expression
    3ms
    Unraveling the impact of cancer-associated fibroblasts on hypovascular pancreatic neuroendocrine tumors. (PubMed, Br J Cancer)
    CAFs drive the growth and metastasis of aggressive PNETs. The CXCR4-SDF1 axis may be a target for antistromal therapy in the treatment of PNET. This study clarifies mechanisms underlying PNET aggressiveness and may guide future therapeutic interventions targeting the tumor microenvironment.
    Journal
    |
    CXCL12 (C-X-C Motif Chemokine Ligand 12) • AGR2 (Anterior gradient 2)
    |
    AGR2 elevation • AGR2 expression
    over2years
    Anterior gradient 2 regulates cancer progression in TP53‑wild‑type esophageal squamous cell carcinoma. (PubMed, Oncol Rep)
    These results suggested that although AGR2 enhanced cell proliferation by inhibiting p53 phosphorylation in TP53‑wild‑type ESCC, the same mechanism did not regulate cell functions in TP53‑mutant ESCC. Thus, AGR2 served an important role in ESCC progression and might be a useful prognostic marker in patients with TP53‑wild‑type ESCC.
    Journal
    |
    TP53 (Tumor protein P53) • AGR2 (Anterior gradient 2)
    |
    TP53 mutation • TP53 wild-type • TP53 expression • AGR2 elevation